v3.26.3
Operating income
 9 Months Ended
Sep. 30, 2026
Other Income and Expenses [Abstract]  
Operating income Operating income
The following table summarizes the operating income during the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Research tax credit1.62.83.15.0
Total1.62.83.15.0
During the nine months ended September 30, 2026, the Company accrued $3.1 million of research tax credit. The tax credit income accrual reflects the expected level on a full year basis of eligible experimental activities, as the Company’s focus continues to shift from clinical development toward commercial readiness activities.